You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Rho kinase activity

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy Trial in Philadelphia (Netarsudil 0.02% Ophthalmic Solution

Not yet recruiting
  • Rhegmatogenous Retinal Detachment
  • Proliferative Vitreoretinopathy
  • Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
  • Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
  • Philadelphia, Pennsylvania
    Wills Eye Physicians - Mid Atlantic Retina
Dec 13, 2022

Amyotrophic Lateral Sclerosis Trial in France, Germany, Switzerland (Fasudil, Placebo)

Active, not recruiting
  • Amyotrophic Lateral Sclerosis
  • Marseille, France
  • +14 more
Jun 2, 2022

Progressive Supranuclear Palsy, Corticobasal Syndrome Trial in San Francisco (Fasudil)

Active, not recruiting
  • Progressive Supranuclear Palsy
  • Corticobasal Syndrome
  • San Francisco, California
    University of California Weill Institute for Neurosciences
May 31, 2022

The Continuous Positive Airway Pressure Effect on Rho-associated

Recruiting
  • Obstructive Sleep Apnea
    • Keelung, Taiwan
      Sleep center
    Sep 18, 2021

    Amyotrophic Lateral Sclerosis Trial in Australia, United States (Fasudil (WP-0512))

    Recruiting
    • Amyotrophic Lateral Sclerosis
    • Fasudil (WP-0512)
    • Phoenix, Arizona
    • +11 more
    Oct 28, 2022

    Protein Kinase A in Prostate Cancer Tissue.

    Not yet recruiting
    • Prostate Neoplasm
    • +2 more
    • prostate biopsy
    • (no location specified)
    Jul 14, 2022

    Metastatic Cancer, Carcinoma, Adenocarcinoma Trial in Cleveland (18F-Clofarabine)

    Recruiting
    • Metastatic Cancer
    • +2 more
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    May 11, 2022

    Chronic GVHD Trial in United States (drug, procedure, other)

    Not yet recruiting
    • Chronic Graft Versus Host Disease
    • Tampa, Florida
    • +4 more
    Aug 10, 2023

    Advanced Cancer, Metastatic Cancer, Solid Tumor Trial in United States (JZP815)

    Recruiting
    • Advanced Cancer
    • +2 more
    • Denver, Colorado
    • +4 more
    Jan 10, 2023

    Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +6 more
    • San Antonio, Texas
      Next Oncology
    Aug 9, 2022

    NSCLC Trial in Seoul (BBT-176, Cetuximab)

    Recruiting
    • NSCLC
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
    • +3 more
    Jan 6, 2023

    Chronic Lymphocytic Leukemia, CLL, SLL Trial in United States (TP-0903, TP-0903 and ibrutinib combination therapy)

    Terminated
    Has Results
    • Chronic Lymphocytic Leukemia
    • +3 more
    • TP-0903
    • TP-0903 and ibrutinib combination therapy
    • Phoenix, Arizona
    • +5 more
    Apr 4, 2022

    Thymic Carcinoma, NSCLC, Refractory Thoracic Tumors Trial in United States (VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab)

    Active, not recruiting
    • Thymic Carcinoma
    • +3 more
    • VEGFR/PDGFR Dual Kinase Inhibitor X-82
    • Nivolumab
    • Palo Alto, California
    • +6 more
    Sep 21, 2022

    Corneal Edema Trial in San Salvador (HCEC-1)

    Active, not recruiting
    • Corneal Edema
    • San Salvador, El Salvador
      Clinica Quesada
    Mar 24, 2022

    Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

    Completed
    Has Results
    • Lymphoma, Large-Cell, Anaplastic
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Jul 26, 2021

    Fuchs Trial in United States (Topical Ripasudil, Topical Placebo)

    Recruiting
    • Fuchs
    • Topical Ripasudil
    • Topical Placebo
    • Palo Alto, California
    • +3 more
    Jan 18, 2023

    GVHD Trial in Hackensack (Telmisartan)

    Active, not recruiting
    • GVHD
    • Hackensack, New Jersey
      Hackensack University Medical Center
    Sep 2, 2022

    NSCLC Trial in Seoul (SNK01 (Super Natural Killer Cells 01), GC, Cetuximab)

    Recruiting
    • Non-small Cell Lung Cancer
    • SNK01 (Super Natural Killer Cells 01)
    • +2 more
    • Seoul, Songpa-gu, Korea, Republic of
      Asan Medical Center
    Jul 15, 2021

    Glaucoma, Open-Angle Trial in San Antonio (Netarsudil Ophthalmic)

    Unknown status
    • Glaucoma, Open-Angle
    • Netarsudil Ophthalmic
    • San Antonio, Texas
      University of the Incarnate Word
    Apr 12, 2020

    Advanced Solid Tumors, Inoperable, Metastasis Trial in Alkmaar, Amsterdam (desatinib or sunitinib or erlotinib or everolimus or

    Terminated
    • Advanced Solid Tumors
    • +2 more
    • desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
    • Alkmaar, Netherlands
    • +1 more
    Nov 18, 2020

    Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL Trial in Japan (Acalabrutinib, Obinutuzumab)

    Active, not recruiting
    • Part1: Advanced B-cell Malignancies
    • +2 more
    • Chiba-shi, Japan
    • +13 more
    Jan 31, 2022

    Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer Trial in Lyon, Toulouse (Pexidartinib, Durvalumab)

    Completed
    • Colorectal Cancer
    • +3 more
    • Lyon, France
    • +1 more
    Sep 2, 2021

    Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

    Completed
    Has Results
    • Myelofibrosis
    • Imetelstat 4.7 mg/kg
    • Imetelstat 9.4 mg/kg
    • Birmingham, Alabama
    • +71 more
    Aug 17, 2021

    NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +14 more
    • Glendale, California
    • +12 more
    Feb 2, 2023

    Chronic Graft-versus-host-disease Trial in United States (Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD)

    Active, not recruiting
    • Chronic Graft-versus-host-disease
    • Belumosudil 200 mg QD
    • +2 more
    • Duarte, California
    • +7 more
    Aug 5, 2022